Drug Approval | October 26, 2022
Zydus receives final approval from USFDA for Micafungin for Injection
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Subscribe To Our Newsletter & Stay Updated
